SGLT2 inhibitor use and renal outcomes in low-risk population with diabetes mellitus and normal or low body mass index
Authors' conclusion
SGLT2 inhibitor use may reduce the risk of eGFR decline and all-cause mortality even in low-risk patients with diabetes and normal or low BMI.
Study context
- Population
- Adults with T2D and body mass index (BMI)<23 kg/m², 2016 to 2020; mean age 61.6 years, mean estimated glomerular filtration rate (eGFR) 84.7 mL/min/1.73 m², median urine albumin-to-creatinine ratio 11.6 mg/gCrpropensity score matched
- Participants
- 648 adults
- Exposure
- SGLT2i vs control
- SGLT2 inhibitorn = 216
- Outcome
- Annual change in eGFR
Methodological detailssingle-centre, propensity-score matched
- Single-centre
- Propensity-score matched
Main finding
As reported in the abstract
Control
0.0
mL/min/1.73 m²/year
SGLT2i
+0.3
mL/min/1.73 m²/year
P = 0.0398
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| All-cause mortalitySGLT2ivs Control | 0.171 (0.041–0.718) | P = 0.0159 | |
| Composite renal outcome (eGFR decline ≥40% from baseline or end-stage kidney disease)SGLT2ivs Control | 0.223 (0.052–0.952) | P = 0.0426 | |
| 0.050.21520Hazard ratio (log scale) |
Cardiovascular disease (CVD)
- SGLT2i use not associated with risk of CVD
Original publication
SGLT2 inhibitor use and renal outcomes in low-risk population with diabetes mellitus and normal or low body mass index. BMJ Open Diabetes Res Care. Published 5 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →